Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp AACR Conference Call Transcript

Apr 12, 2021 / 12:00PM GMT
Release Date Price: $92.61 (-1.65%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines conference call. (Operator Instructions) As a reminder, today's program is being recorded.

I would now like to introduce your host for today's program, Kristin Hodous of the Blueprint Medicines. Please go ahead.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicines conference call to discuss our AACR 2021 data presentation. You can access the press releases announcing the data as well as the slides that we'll be reviewing today by going to the investors & media section of our website at www.blueprintmedicines.com.

With me on the call today are Jeff Albers, our Chief Executive Officer; Dr. Fouad Namouni, our President of Research and Development; and Dr. Becker Hewes, Chief Medical Officer.

Before we get started, I would like to remind everyone that statements we make on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot